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Redox regulationBy the time it was appreciated that the positive inotropic effect of cardiac glycosides is due to inhibition of the
membrane Na+–K+ pump, glycosides had been used for treatment of heart failure on an empiric basis for
~200 years. The subsequent documentation of their lack of clinical efﬁcacy and possible harmful effect largely
coincided with the discovery that a raised Na+ concentration in cardiac myocytes plays an important role in
the electromechanical phenotype of heart failure syndromes. Consistent with this, efﬁcacious pharmacolog-
ical treatments for heart failure have been found to stimulate the Na+–K+ pump, effectively the only export
route for intracellular Na+ in the heart failure. A paradigm has emerged that implicates pump inhibition in
the raised Na+ levels in heart failure. It invokes protein kinase-dependent activation of nicotinamide adenine
dinucleotide phosphate oxidase (NADPH oxidase) and glutathionylation, a reversible oxidative modiﬁcation,
of the Na+–K+ pump molecular complex that inhibits its activity. Since treatments of proven efﬁcacy reverse
the oxidative Na+–K+ pump inhibition, the pump retains its status as a key pharmacological target in heart
failure. Its role as a target is well integrated with the paradigms of neurohormonal abnormalities, raised
myocardial oxidative stress and energy deﬁciency implicated in the pathophysiology of the failing heart.
We propose that targeting oxidative inhibition of the pump is useful for the exploration of future treatment
strategies. This article is part of a Special Issue entitled “Na+ Regulation in Cardiac Myocytes”.
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The Na+–K+ pump has justiﬁably been referred to as “the oldest
pump” [1]. It was theﬁrst of the family of P-type ATPases to be discovered
[2] and it had been a therapeutic target for treatment of heart failurewith
cardiac glycosides for almost 200 years [3] before it was appreciated that
the glycosides cause Na+–K+ pump inhibition [4]. The glycoside-induced
increase in the intracellular Na+ concentration ([Na+]i) causes an in-
crease in [Ca2+]i via reduced net Na+–Ca2+ exchange-mediated Ca2+
export. The increase in [Ca2+]i then enhances contractility [5]. The dem-
onstration of ouabain bound to the Na+–K+ pump molecular complex
in its three-dimensional crystal structure [6,7] would have completed
a perfect bench-to-bedside integration ofmolecular structure and func-
tion with one of the most classical pharmacological paradigms known.
However, when efﬁcacy was ﬁnally examined in a placebo-controlled
trial in heart failure, this perfect integration was challenged by the bed-
side reality: there was no effect of digoxin on overall survival [8] and
even a decrease in some patient subgroups [9]. A recent study raised
serious doubts about the safety of digoxinwhen used for control of ven-
tricular rate in atrial ﬁbrillation [10], the main indication for which it is
still commonly used. In addition to therapeutic use of cardiac glyco-
sides, one of these, ouabain, is secreted endogenously and implicated
in the pathogenesis of hypertension. The complex mechanisms pro-
posed for this have been comprehensively reviewed recently [11]. An
increase in the synthesis of endogenous ouabain has also been reported
in heart failure but it seems unlikely that this has signiﬁcant effects on
the heart as reviewed [12].
While the Na+–K+ pump has lost its status as a useful target for
treatment of heart failure with cardiac glycosides, it remains critically
important for newer treatments. Here we review the Na+–K+ pump's
role in current evidence-based treatments, how this role may be inte-
grated with molecular and cellular mechanisms for the pathogenesis
of the heart failure syndrome and how the relationship between treat-
ment efﬁcacy and effects of treatments on the Na+–K+ pump has led
to a paradigm of redox-dependent regulation of pump activity.Fig. 1. Neurohormonal abnormalities, cytosolic Na+, oxidative stress and energymetabolism
in heart failure. Neurohormones activate NADPH oxidase via genomic and non-genomic
pathways. Superoxide (O2•−) inhibits the Na+–K+ pump and activates the late Na+ current.
Reduced export and enhanced inﬂux increases [Na+]i which, in turn, reduces mitochondrial
[Ca2+] and increases mitochondrial O2•− synthesis. Oxidative modiﬁcation and inhibition of
ATP synthase reduces ATP synthesis. β3 AR activation may counteract effects of the other
receptors, in part by reducing cAMP levels in critical microdomains.2. Intracellular Na+ and the Na+–K+ pump in heart failure
Many studies have shown that [Na+]i is raised in the myocardium
in heart failure and this is believed to contribute to the clinical manifes-
tations of contractile abnormalities and arrhythmias [13,14]. These
adverse effects occur in part because Na+–Ca2+ exchange increases
cytosolic Ca2+. Ca2+-induced diastolic Ca2+ release from the sarcoplas-
mic reticulum then reduces the amount available for release in systole
[13,15]. Raised [Na+]i is also thought to contribute to the heart failure
phenotype by reducing mitochondrial Ca2+ uptake which in turn in-
creases production of reactive oxygen species [16]. An inhibitory oxida-
tive modiﬁcation of mitochondrial ATP synthase [17] then reduces
energy supply [18] (Fig. 1).
Raised [Na+]i can result from enhanced Na+ inﬂux. Of pathways
implicated in heart failure, the late Na+ current has attracted much
recent attention. Ca2+/calmodulin activated by reactive oxygen species
augments the current, and an increase in [Na+]i from this source can
contribute to diastolic [Ca2+]i accumulation. Augmentation of the late
Na+ current may also contribute to prolongation of the action potential
duration and to arrhythmogenesis [19]. Targeting the current therapeu-
tically in heart failure is under clinical investigation [20].Raised [Na+]i can also result from reduced efﬂux mediated by the
Na+–K+ pump, effectively the only export route for Na+. Most studies
examining the myocardial Na+–K+ pump in heart failure have reported
reduced activity. The relative contribution of enhanced inﬂux versus
reduced efﬂux to the increase in [Na+]i and to abnormalities in [Ca2+]i
and cardiac electrophysiology has recently been evaluated quantitatively
using a mathematical model. A decrease of pump activity was the most
important contributor to an increase in [Na+]i and abnormalities of
Ca2+ handling and action potentials [21]. Since decreased electrogenic
Na+–K+ pump current (Ip) precedes a reduction in sarcoplasmic Ca2+
content and cytoplasmic Ca2+ transients in myocytes from guinea pigs
with heart failure [22], pump inhibition may be a primary abnormality.2.1. The Na+–K+ pump as a contemporary pharmacological target in
heart failure
In view of the potential role of Na+–K+ pump abnormalities in
heart failure it is of interest to consider the relationship between out-
comes of clinical trials and the effect we have found the trial treatments
have on the Na+–K+ pump in cardiac myocytes. Such an approach is ef-
fectively an exercise in reverse engineering, useful for understanding
basic mechanisms of the heart failure syndrome [23]. Unless indicated,
we have administered the treatments to rabbits in vivo and then studied
the Na+–K+ pump inmyocytes ex vivo. Most studies were performed in
normal rabbits, indicating that the results can be attributed to a primary
pharmacological action rather than to a treatment-induced improve-
ment of underlying pathology via independent mechanisms. Measure-
ments of Ip in cardiac myocytes were performed using standardized
criteria [24] in accordance with those originally described by Gadsby
et al. [25,26].
The most commonly used evidence-based treatments for human
heart failure are based on the “neurohormonal hypothesis” [27] and
antagonise activation of the renin–aldosterone–angiotensin system or
adrenergic hyperactivity [23]. Treatment of rabbitswith the angiotensin
converting enzyme (ACE) inhibitor captopril, increased Ip in voltage
clamped myocytes studied ex vivo and correspondingly decreased
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similar effect on Ip in a disease model when a decrease of Ip inmyocytes
from rabbits with alloxan-induced diabetes was reversed by treatment
with the angiotensin receptor antagonist losartan [29]. Angiotensin
promotes synthesis of aldosterone that may have harmful effects, in
part because it upregulates NADPH oxidase [30]. Consistent with clini-
cal efﬁcacy of the aldosterone receptor antagonist spironolactone, treat-
mentwith spironolactone reversed a decrease in Ip and a corresponding
increase in [Na+]i caused by in vivo administration of aldosteronemim-
icking serum levels in heart failure [31]. Treatment of normal rabbits
[32] with the β1 adrenergic receptor (β1 AR) antagonist metoprolol,
increased Ip and abolished a decrease in Ip in myocytes from rabbits
with heart failure [33]. Nitric oxide (NO) donors are not widely used
in heart failure but nevertheless are of proven beneﬁt [34]. We have
not examined in vivo effects of NO donors, but in vitro exposure of volt-
age clamped myocytes increases Ip [24].
In vitro activation of β3 adrenergic receptors increases Ip of cardiac
myocytes [35] as does in vivo activationwith an agonist [36]. Treatment
with a β3 AR agonist in vivo also reverses a decrease in Ip in myocytes
isolated from rabbits with diabetes, a condition predisposing to heart
failure [36]. As expected from activation of the Na+–K+ pump, acute
intravenous administration of a β3 AR agonist has opposite effects on car-
diac performance in sheepwith andwithout heart failure, consistentwith
the known differential effects on excitation–contraction coupling with
changes in [Na+]i from low- and high baseline levels [35]. The β3 AR is
up-regulated in human heart failure. This has widely been considered
maladaptive. However, when seen in the light of the β3 AR-dependent
Na+–K+ pump activation, we believe human studies actually suggest β3
AR agonists might be beneﬁcial, although the evidence is indirect as
reviewed [37]. We are currently examining the effect of treatment withFig. 2. Structure and catalytic cycle of the Na+–K+ pump. A. Three-dimensional structure o
are between the 2 unbroken green lines. The β subunit and the FXYD proteins are single-tra
cysteine residues in β1 subunit (C46) and FXYD (C2) are indicated. The expanded section i
subunits (broken lines). B. Albers-Post scheme for Na+–K+ pump catalytic cycle. When 3 Na+
and locked with phosphorylation of the α subunit (2), causing occlusion of Na+ ([Na+]3) wi
afﬁnity decreases with E1P → E2P change. K+ is bound (4), the gate is closed and the res
E2PiK2+ product state of dephosphorylation (in box) is the conformation for which the three-
bering corresponds to the FXYD1 sequence and begins at 1 after the signal peptide (not show
labelled C1 and C2. TM indicates the transmembrane domain.a β3 AR agonist on the Na+–K+ pump and on clinical features in rabbits
with heart failure. A human clinical trial is planned [38].
The role of the Na+–K+ pump, and by inference [Na+]i, in heart
failure can also be implicated from the effect on Ip of treatments
that have turned out to be harmful. Amiodarone increases mortality
in patients with class III heart failure [39] and Ip of myocytes isolated
from rabbits given the drug is reduced [40]. The β1 AR partial agonist
Xamotarol increases mortality in human heart failure [41] and the
drug is expected to activate adenylyl cyclase-dependent signalling
that inhibits Ip [42], at least when activation occurs in vitro.
In summary, there is a robust relationship between clinical efﬁcacy
of treatments of human heart failure and the effects such treatments
have on the Na+–K+ pump when studied in rabbit cardiac myocytes.
The pump therefore retains its status as a therapeutic target in heart
failure that it ﬁrst earned from interaction with cardiac glycosides.
However, contrary to the original paradigm, stimulation and not inhibi-
tion of the pump is beneﬁcial.
3. Protein kinase-dependent signalling and the Na+–K+ pump as a
treatment target
It is widely reported that phosphorylation of the FXYD1 protein that
associates closely with the α/β pump heterodimer (Fig. 2A) stimulates
theNa+–K+ pump in cardiacmyocytes as reviewed [43]. However such
an effect of FXYD1 phosphorylation cannot be immediately reconciled
with hyperphosphorylation of FXYD1 [44] and reports of Na+–K+
pump inhibition [22,33] in heart failure, nor does stimulation of the
pumpmediated by FXYD1 phosphorylation readily explain the increase
in Ip induced by treatment with β1 AR blockers and ACE inhibitors
[28,32,33] and the clinically beneﬁcial effects of these drugs [23] despitef α/β/FXYD complex in a conformation analogous to E2PiK2+. Transmembrane domains
nsmembrane spanning while 10 helices of the α subunit span the membrane. Reactive
llustrates proximity of the glutathionylation site to hydrogen bonds between β- and α
ions have been bound to the E1 conformation (1) the cytoplasmic access gate is closed
thin the molecule. A gate opens to the outside and Na+ is released (3) when its binding
ultant conformational change of the pump stimulates its dephosphorylation (6). The
dimensional crystal structure is known. C. Sequence alignment of FXYD1-3 and 7. Num-
n). Conserved residues are marked with ﬁlled circles with conserved cysteine residues
Fig. 3. Scheme proposed for nitric oxide-dependent Na+–K+ pump regulation. Superoxide
(O2•−) is synthesised when receptor-dependent protein kinase Cs phosphorylates p47phox
and activates NADPH oxidase. Reaction of O2•− with NO leads to the formation of the
biologically highly reactive species ONOO−. This promotes glutathionylation-induced
Na+–K+ pump inhibition. However,whenNO activates a sGC/cGMP/PKG/PP2A-dependent
pathway, PP2A dephosphorylates p47phox and inactivatesNADPHoxidase, allowing reversal
of glutathionylation of the pump and relief from inhibition. Spatial dependence of NO con-
centrations relative to NADPH oxidase and the Na+–K+ pump and/or a differential NO
concentration-dependence of its effects to form ONOO− or activate sGC might determine
whether NO increases or decreases pump activity.
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ARs- and angiotensin II (Ang II) receptors are coupled to activation of
protein kinase A (PKA) and -C (PKC), thus in vivo treatment with β1
AR blockers or ACE inhibitors should reduce PKA- and PKC activities
by reducing adrenergic activity and levels of Ang II in the myocardium.
This should also reduce phosphorylation of FXYD1. We have conﬁrmed
this experimentally in normal rabbits [32]. If FXYD1 phosphorylation
were to stimulate Na+–K+ pump activity, β1 AR blockers and ACE
inhibitors should therefore accentuate harmful effects of the raised
[Na+]i in heart failure.
3.1. Protein kinase-dependent redox signalling and the Na+–K+ pump
Since phosphorylation of the Na+–K+ pump molecular complex
cannot readily account for effects of the two best documented and
most commonly used treatment modalities in heart failure on Na+–K+
pump function we have examined if oxidative posttranslational modiﬁ-
cations might play a role. Oxidative modiﬁcations can affect structure
and function of proteins in a manner analogous to phosphorylation
[45] and seemed a plausible alternative because heart failure is associat-
edwith increasedmyocardial oxidative stress [46] and because chemical
oxidants can inhibit Na+–K+ ATPase in membrane fragments [47] and
pump activity in cardiac myocytes [48]. Of the oxidative modiﬁcations,
a disulphide bond between cysteine residues on the cytosolic tripeptide
glutathione (GSH) and a protein is of particular interest because it is
stable, yet reversible [45].
We examined if receptor-coupled activation of oxidative
signalling and glutathionylation of the Na+–K+ pump contribute
to pump regulation. Exposure of myocytes to Ang II increased the
co-immunoprecipitation of the membranous p22phox subunit of
NADPH oxidase with the cytosolic p47phox subunit in myocyte lysate
consistent with the translocation of p47phox to the cell membrane
that is required for activation of NADPH oxidase [49]. It also increased
co-immunoprecipitation of the Na+–K+ pump molecular complex
with p47phox while it decreased Ip. The decrease in Ip was abolished by
blocking translocation of p47phox, and hence NADPH oxidase activation,
and by blocking εPKC activation [49]. These results are consistent with
PKC-dependent phosphorylation of p47phox necessary for its transloca-
tion. The Ang II-induced activation of oxidative signalling was associat-
edwith glutathionylation of theβ1 subunit of the Na+–K+ pump [50]. A
decrease inβ1 subunit glutathionylation after treatmentwith anACE in-
hibitor suggests that Ang II has the same effect in vivo [32]. Mutational
studies of Na+–K+ pumps expressed in Xenopus oocytes identiﬁed cys-
teine 46 (C46) as the reactive residue in the β1 subunit [50] and, consis-
tent with the NADPH oxidase-dependence of Ang II-induced inhibition
of Ip in cardiac myocytes [49], there was a causal relationship between
β1 subunit glutathionylation and pump inhibition [50].
We have also examined if β1 AR-dependent signalling causes down-
stream oxidative modiﬁcation of the Na+–K+ pump. In in vitro studies
we used forskolin to activate adenylyl cyclase that is coupled to the β1
AR rather than a receptor agonist because of the imperfect selectivity
of the available agonists. Forskolin activated NADPH oxidase via PKA-
and PKC-dependent pathways and inhibited Ip of cardiac myocytes
[42]. It also induced glutathionylation of the β1 Na+–K+ pump subunit
and a decrease in Ip that was abolished by inhibition of PKA, εPKC or
NADPH oxidase [42]. Consistent with these results, in vivo β1 AR block-
ade in normal rabbits inhibited εPKC and NADPH oxidase activation,
reduced β1 Na+–K+ pump subunit glutathionylation and increased Ip
of cardiac myocytes [32]. The β1 AR blockade also decreased β1 pump
subunit glutathionylation and increased Ip in rabbits with heart failure
[33].
The β1 Na+–K+ pump subunit is glutathionylated at baseline and,
in contrast to effects mediated by β1 AR-dependent signalling, the
NO-dependent pathways coupled to the β3 AR cause a decrease in the
β1 subunit glutathionylation and an increase in Ip with in vitro [35] as
well as with in vivo activation of the receptor [36]. NO-dependentsignalling can occur via nitrosylation of target cysteine residues
[51] and Yukasev et al. [52] have quoted us as having reported that
nitrosylation is an intermediate step in glutathionylation of the β1
Na+–K+ pump subunit. If nitrosylation of the β1 subunit were to ac-
count for the β3 AR- and NO-dependent stimulation one would have
to assume the effect of nitrosylation onNa+–K+pump function is oppo-
site to that of glutathionylation. However, we have never reported
nitrosylation of the β1 subunit, and we have previously shown that
the “classical” [51] soluble guanylyl cyclase/cGMP/PKG dependent
pathway can account for NO-dependent Na+–K+ pump stimulation.
The pump stimulation is okadaic acid- sensitive implicating activation
of protein phosphatase in the stimulation [24]. Phosphatase-mediated
dephosphorylation of the p47phox subunit has been implicated in inhibi-
tion of NADPH oxidase in neuotrophils [53] and the balance between
PKC-dependent phosphorylation and protein phosphatase-mediated
dephosphorylationwas suggested to determineNADPHoxidase activity
[54]. We are currently examining if protein phosphatase-dependent
dephosphorylation of p47phox can account for the effect of okadaic
acid-sensitive activation of the classical pathway on Na+–K+ pump
activity in cardiac cells. Such activation in combination with a β3
AR-dependent reduction of cyclic adenosine monophosphate
(cAMP) levels in critical microdomains [55], might relieve oxidative
inhibition of the Na+–K+ pump and hence contribute to β3
AR-dependent pump stimulation. The role the classical NO-dependent
pathway may have in Na+–K+ pump stimulation is summarized in
Fig. 3.3.2. FXYD proteins and redox-dependent Na+–K+ pump regulation
While phosphorylation of FXYD1 is implicated in regulation of
cardiac myocyte Na+–K+ pump, functional phosphorylation sites on
FXYD2-7 have not been ﬁrmly demonstrated. However, two cysteine
residues in the cytoplasmic terminal, named C1 and C2 in Fig. 2C, are
conserved in the 7-member mammalian family. While most cysteine
residues in proteins do not undergo oxidative modiﬁcations, C1 and
C2 are good candidates because they are mostly ﬂanked by the basic
amino acids lysine and arginine. FXYD1, native to cardiac myocytes,
and other FXYD proteins that we expressed in Xenopus oocytes
were susceptible to glutathionylation. Mutagenesis identiﬁed C2 but
not C1 as reactive, with reactivity of C2 depending on ﬂanking basic
amino acids. The three dimensional structure suggested proximity
to basic amino acids in the α subunit might account for differences
98 C.-C. Liu et al. / Journal of Molecular and Cellular Cardiology 61 (2013) 94–101in reactivity between C1 and C2 [56]. A reactive cysteine in the C2
position of FXYD proteins was critical for reversal of glutathionylation
of C46 of the β1 subunit and Na+–K+ pump inhibition induced by
chemical oxidants or exposure of myocytes to Ang II. Results obtained
in Xenopus oocytes expressing FXYD proteins with- and without a
reactive C2 independently supported this conclusion (see Bibert
et al., for details) [56]. Of importance for receptor-coupled signalling,
a decrease from baseline C46 glutathionylation and an increase in Ip
induced by a β3 AR agonist was also dependent on a reactive C2 [56].
As discussed previously [57], glutathionylation of PKA and PKC can
inhibit activity of the kinases and an oxidant signal might therefore
inhibit Na+–K+ pump activity by decreasing the phosphorylation of
FXYD1 that ismaintained by constitutively active protein kinases. How-
ever, co-expression of FXYD1 with α1/β1 subunits in Xenopus oocytes
prevents a decrease in Ip induced by an oxidant signal that otherwise
occurswhen onlyα1/β1 subunits are expressed. This effect is eliminated
when the reactive C2 in the wild-type FXYD1 is mutated to a non-
reactive amino acid residue while leaving phosphorylation sites on
FXYD1 intact [56]. The decrease in Ip is also eliminated when the reac-
tive C46 in the β1 subunit is mutated to a non-reactive residue or if α1
subunits are co-expressed with β2- or β3 subunits that do not have a re-
active cysteine residue [50]. Redox-sensitivity of protein kinases cannot
account for these results inXenopus oocytes. Oxidative inhibition of pro-
tein kinases also cannot account for Na+–K+ pump inhibition we have
attributed to pathways that are coupled to the β1 AR [42] and Ang II re-
ceptors [49] in cardiac myocytes because in vivo treatments with a β1
AR antagonist or an ACE inhibitor increase Ip while the treatments de-
crease activities of PKA and PKC. As expected from the decrease in pro-
tein kinase activities, treatment with the β1 AR antagonist decreased
phosphorylation of FXYD1. The effect of the catalytic subunit of PKA in-
cluded in patch pipette solutions to decrease Ip [32] independently sup-
ports the conclusion that the PKA-dependent Na+–K+ pump inhibition
we report is not secondary to oxidation-induced inhibition of PKA and a
decrease in phosphorylation of FXYD1.
3.3. Glutathionylation of the α Na+–K+ pump subunit
We have been unable to identify glutathionylation of the α1 Na+–K+
pump subunit in cardiac myocytes [42,50,56] and, while we found that
oxidant stress decreases Ip of Xenopus oocytes when α1 subunits are
co-expressed with wild-type β1 subunits, the absence of any decrease in
Ip when α1 subunits are co-expressed with C46-mutated β1 subunits
[50] indicates that no functional effect could be attributed to
glutathionylation of the α1 subunits in our experiments. In contrast,
Petrushenko et al. [58] and Yakushev et al. [52] have recently reported
that several cysteine residues on the α1 subunit are susceptible to
glutathionylation. Glutathionylation inNa+–K+ATPase-enrichedmem-
brane fragments, detected under baseline conditions, was enhanced
with exposure to oxidised GSH. The exposure decreased Na+–K+
ATPase activity but, as pointed out by the authors, “removal of basal
glutathionylation by DTT (dithiothretiol) was not followed by an alter-
ation of the Na+–K+ ATPase activity”. These results contrast the strong
correlation between an increase in Ip and a decrease in β1 subunit
glutathionylation from baseline that occurs when the β3 AR is acti-
vated in cardiac myocytes [35]. A causal relationship between
glutathionylation of the α1 subunit and Na+–K+ ATPase activity re-
mains to be established. Mutation of the implicated cysteine residues
would be essential for this. It would also be important to establish if
receptor-coupled signalling alters α1 subunit glutathionylation.
Petrushenko et al. [58] proposed that hypoxia is a physiological stim-
ulus that induces regulatory S-glutathionylation of theα1Na+–K+pump
subunit in rat myocardium and an associated decrease in Na+–K+
ATPase activity. However, functional effects attributed to α1 subunit
glutathionylation were only evident at an ATP concentration b500 μM
[58], an unlikely concentration under physiological conditions and also
not expected to be encountered with the modest decrease in the ATPconcentration that occurs in heart failure [59]. Yakushev et al. [52] re-
ferred to a hypoxia-induced decrease in Na+–K+ ATPase activity of 20%
that we had attributed to glutathionylation of C46 in the β1 subunit and
compared it with a much more extensive inhibition of activity known to
occur in ischemic heart. This comparison is invalid. We have reported
on the effect of myocardial infarction on glutathionylation of the β1
subunit [50] but not on the effect of hypoxia on glutathionylation, and
we have not reported on any effect of infarction or hypoxia on Na+–K+
pump function.4. Structural changes during the Na+–K+ pump cycle and
glutathionylation-dependent function
4.1. Susceptibility of C46 in β1 Na+–K+ pump subunit to
glutathionylation
Since GSH is hydrophilic and strictly cytosolic, glutathionylation of
C46 is counterintuitive in view of its location in the transmembrane seg-
ment (Fig. 2A), with its sulfhydryl group facing the lipid bulk phase. The
three dimensional structure that indicates this location is known in only
one of the Na+–K+ pump's conformations andwe subsequently showed
that susceptibility to glutathionylation of C46 depends on the conforma-
tional states the pump undergoes in its catalytic cycle (Fig. 2B) [60]. The
β subunit formsmany contacts with transmembrane segments 7 (αM7)
and 10 of the α subunit [61] with polar residues lining the interface be-
tween the subunits from the cytoplasm to C46 [62] and, usingmolecular
dynamics simulations, Thøgersen and Nissen [62] demonstrated that
minor structural changes in the pump molecular complex are likely to
cause a membrane deformation that yields a hydrophilic environment
for C46. This might explain the conformation-dependence of access for
GSH.
There are no neighbouring basic amino acids in the primary
sequence of the β1 subunit that would reduce pKa of the sulfhydryl
group to promote glutathionylation of C46. However, a cluster of 4 argi-
nines and one lysine near the C terminus of αM10 is ~15 Å from the
side chain of C46 in the known crystal structure [61] and might move
in response to Na+ binding. Such movement and membrane deforma-
tion allowing access of the sulfhydryl group of C46 might provide an
environment promoting glutathionylation of C46. Correlation between
conformation-dependent access for trypsin to digest the β1 subunit
and the C terminus of αM10 [63] would seem consistent with such
speculations.
Speculations about changes in pKa of C46 during the catalytic cycle are
based on the tacit assumption that glutathionylation must always be
accounted for by physicochemical properties of the glutathionylated cys-
teine residue. However, in intact cells, glutathionylation of proteins can be
catalysed by glutathione S-transferase (GST) [64], and we have prelim-
inary data indicating that exposing Na+–K+ ATPase-enriched mem-
brane fragments to the π isoform of GST facilitates glutathionylation
of the β1 subunit (unpublished). Similarly, deglutathionylation is not
necessarily only described in physicochemical terms. Deglutathionylation
of proteins is selectively catalysed by glutaredoxin 1 (Grx1). Grx1
co-immunoprecipitates with FXYD1 and the β1 pump subunit in cardiac
myocyte lysate [56] and addition of recombinant Grx1 to the lysate
reverses β1 subunit glutathionylation induced by oxidative stress [56].
When included in patch pipette solutions, recombinant Grx1 also
counteracted oxidative stress-induced inhibition of Ip [50]. We have
recently found that translocation of Grx1 may contribute to the in vivo
deglutathionylation that occurswith blockade of theβ1 AR [32]. A balance
between opposing effects of πGST and Grx1 may be important in deter-
mining the level of glutathionylation of the Na+–K+ pump in a manner
reminiscent of the roles kinases and phosphatases have in determining
phosphorylation of proteins. Differential access of πGST and Grx1 to
the Na+–K+ pump in its different conformations may contribute to
conformation-dependence of glutathionylation in cells.
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The ~305 Da negatively charged GSH adduct may weaken the
interaction of tyrosines 40 and 44 of the β subunit with αM7
(Fig. 2A) [61], reminiscent of the effect mutation the tyrosines have
on αM7/β1 interaction [65]. Consistent with this, glutathionylation
decreases the α/β co-immunoprecipitation. A disruption of the α/β
heterodimer with glutathionylation is also supported by its increased
sensitivity to trypsin digestion, in particular the sensitivity of the β
subunit [60].
Assuming co-immunoprecipitation reﬂects a direct physical inter-
action, a decrease in FXYD1/α1- and an increase in FXYD1/β1 subunit
co-immunoprecipitation with oxidative stress can also be viewed in
structural terms. The signature motif of FXYD10 (non-mammalian
FXYD1 homologue) in shark rectal gland Na+–K+ ATPase forms a net-
work of hydrogen bonds to α and β subunits extracellularly, while it
forms only a single hydrogen bond toα in the transmembrane segment
[61]. Positively charged basic amino acids near the cytosol-membrane
interface may stabilize FXYD/α interaction because of the electrostatic
attraction they share to negative charges at the innermembrane leaﬂet.
Electrostatic switch theory for interaction of proteins with membranes
[66] suggests such stabilization might be disrupted when the C2-
equivalent of FXYD proteins acquires the negatively charged GSH
adduct. However, interaction of the extracellular FXYD motif with the
β subunit should remain unaffected, shifting the relative strength of
association of FXYD proteins from the α- towards the β subunit as
suggested by the co-immunoprecipitation experiments.
Even with structural changes that occur during the Na+–K+ pump
cycle, the large distance between C46 in the β1 subunit and C2 in FXYD
proteins (Fig. 2A) precludes simple disulﬁde exchange between the
cysteine residues as a mechanism for their functional interaction, and
a more complicated scheme needs to be invoked. Interaction of the
Na+–K+ pump molecular complex with πGST and Grx1 as possible
candidate partners can be involved in such a scheme. Grx1 activation
may occur when conformational changes in proteins or multimeric pro-
tein complexes allow access for it to target disulﬁde bonds [67], and
conformation-dependence of co-immunoprecipitation of Grx1 with the
β1 subunit of Na+–K+ ATPase [60] is consistent with conformation-
dependence of Grx1-mediated de-glutathionylation. With interaction
of Grx1 and possibly πGST with cysteine residues in the C2 position of
FXYD proteins and C46 in theβ1 subunit in structural conformations cor-
responding to different sub-states of the pump's catalytic cycle (Fig. 2B),
a large number of schemes for C2/C46 interaction become possible.
4.3. Glutathionylation and Na+i/K
+
i-dependence of Na
+–K+ pump
turnover
A monensin-induced increase in [Na+]i renders the β1 Na+–K+
pump subunit resistant to glutathionylation in intact myocytes [60],
and an Ang II-induced increase in oxidative stress inhibits Ip of voltage
clamped myocytes when [Na+] in patch pipette solutions is near phys-
iological intracellular levels but not when it is high or when pipette
solutions are K+-free [60]. The in vivo relevance of this is highlighted
by the dependence of an increase in Ip on [K+] in pipette solutions
when myocytes are studied ex vivo after treatment of rabbits with an
ACE-inhibitor [68]. Corresponding results have been obtained in diabe-
tes, known to be associated with oxidative stress. Diabetes induced
experimentally in rabbits caused a decrease in Ip that was dependent
on the pipette [K+] as was reversal of the decrease when the rabbits
had been treated with an Ang II receptor antagonist [29].
The dependence of oxidative Na+–K+ pump inhibition on [Na+]i
and [K+]i is consistent with the susceptibility of the β1 subunit to
glutathionylation in different conformational states of the pump.
Binding of Na+ occurs to Na+–K+ pump species in the E1 conformation
(Fig. 2B), a conﬁrmation that is highly susceptible to glutathionylation[60]. Since Na+ binds in competition with K+, kinetically incompetent,
susceptible E1 species that have bound K+ accumulate when [K+]i is
high while a high [Na+]i has the opposite effect, i.e. it is expected to de-
crease the abundance of E1 species and hence decrease glutathionylation.
Such a dependence of glutathionylation on [Na+]i and [K+]i has impor-
tant consequences for pump function.
Glutathionylation-dependent Na+–K+ pump inhibition could be-
come self-amplifying if an increase in [Na+]i were to increase oxidative
stress (Fig. 1). However, the increase in the [Na+]i: [K+]i ratio with
pump inhibition should reduce susceptibility to glutathionylation and
hence eliminate the risk of self-amplifying pump inhibition abolishing
all function during oxidative stress. Although less abundantly expressed
than pumpswithβ1 subunits, pumpswithβ2 orβ3 subunits should pro-
vide some additional back-up function because these subunits are not
susceptible to glutathionylation [50]. [Na+]i- and [K+]i-dependence
of β1 subunit glutathionylation is also expected to mediate receptor-
coupled, protein kinase-dependent regulation of Na+–K+ pump func-
tion in amanner thatmight traditionally have been attributed to effects
on ligand binding sites. For example, the Ang II-induced pump inhibi-
tion at low- but not high [Na+]i [60] we referred to above that might
have been due to effects of Ang II-dependent signalling on Na+ binding
can also be accounted for by the inverse relationship between [Na+]i
and the susceptibility of C46 in β1 subunits to glutathionylation. This re-
lationship would effectively mimic a change in the pump's Na+ afﬁnity.5. Summary and perspectives
The idea that inhibition of the Na+–K+ pump is desirable in heart
failure became untenable when it was recognized that cardiac glyco-
sides are ineffective and that raised [Na+]i is harmful. However, effects
of current evidence-based treatments on oxidative modiﬁcation and
function of Na+–K+ pump are highly compatible with the neurohor-
monal hypothesis. Since receptor-coupled signalling targeted in heart
failure activates NADPH oxidase or up-regulates components of it, the
effects are also compatible with the ﬁrmly established role of oxidative
stress in the pathogenesis of heart failure. Neurohormone-mediated
oxidative inhibition of the pump can also be integrated with the role
raised [Na+]i has in mitochondrial production of ROS and uncoupling
from ATP synthesis (Fig. 1) in a scheme that readily integrates major
current paradigms in the pathophysiology of heart failure syndrome.
The relationship between outcomes of clinical trials in heart failure
and effects the treatments have on theNa+–K+pumpandoxidative sig-
nalling pathways that regulate it indicate that the pump is an important
treatment target. However, in contrast to the role classically assigned to
the Na+–K+ pump when targeted with cardiac glycosides, we propose
the newer evidence-based treatments target the pump indirectly via
the effect they have on the pathways that modulate oxidativemodiﬁca-
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